Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome

Serum samples from patients with meningococcal disease were examined for the presence of IL-6, TNF-alpha, and LPS. Median serum concentration of IL-6 was 1,000 times higher in patients with septic shock (189 ng/ml) than in patients with bacteriaemia, meningitis, or combined septic shock and meningitis. 11 of 21 patients with serum levels greater than 3.0 ng/ml died, whereas all 58 patients with serum levels at less than or equal to 3.0 ng/ml, survived. All four patients with serum IL-6 levels greater than 750 ng/ml, died. IL-1 was detected in serum from three patients who also had high serum levels of IL-6, TNF-alpha, and LPS, and rapidly fatal courses. IL-6 appeared to be released into serum later than TNF-alpha, and was detected in serum for up to 36 h. The half-life of IL-6 and TNF-alpha was calculated to be 103 +/- 27 min and 70 +/- 11 min, respectively. These data indicate that a complex pattern of cytokines exists in serum from patients with meningococcal septic shock, and that the release of IL-6 and IL-1, in addition to TNF-alpha, is associated with fatal outcome.

[1]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[2]  P. Conlon.  A rapid biologic assay for the detection of interleukin 1. , 1983, Journal of immunology.

[3]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[4]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Aarden,et al.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli. , 1987, Journal of immunology.

[6]  C. Maury,et al.  Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection , 1987, The Journal of experimental medicine.

[7]  B. Beutler,et al.  The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.

[8]  P. Brandtzaeg,et al.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[9]  C. Nathan,et al.  Phase I trial of recombinant interferon gamma in cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.

[11]  L. Aarden,et al.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. , 1988, Clinical and experimental immunology.

[12]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[13]  P. Lansdorp,et al.  Production of hybridoma growth factor by human monocytes , 1987, European journal of immunology.

[14]  H. Schreiber,et al.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Clark,et al.  Multiple actions of interleukin 6 within a cytokine network. , 1988, Immunology today.

[16]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.